Long-Term Safety and Efficacy Results in Hepatitis C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir +/- Ribavirin in the Topaz-I and Topaz-Ii Trials
International Liver Congress / 54Th Annual Meeting of the European-Association-For-The-Study-Of-The-Liver (Easl), Date: APR 10-14, 2019, Location: Vienna, AUSTRIA, Sponsors: European Assoc Study Liver
